Deciphera Pharmaceuticals Executive Compensation (FY23)
DCPH · Executive and director compensation, fiscal 2022 to 2023
The paid brief on Deciphera Pharmaceuticals
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (DEF 14A): April 25, 2024
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
229 figures on this page, cited to the filing that reported them. See the citations
More on Deciphera Pharmaceuticals
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2022 to fiscal 2023
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Steven Hoerter: $3,554,485 → $6,010,712 (69.1% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Deciphera Pharmaceuticals' chief executive and what were they paid?
Total compensation for Steven Hoerter, President and Chief Executive Officer, came to $6,010,712 in fiscal 2023. Hoerter's total was 69.1% higher than the $3,554,485 reported for fiscal 2022.
Which companies are in Deciphera Pharmaceuticals' peer group?
Companies named in the disclosed peer group include Agios Pharmaceuticals, Amicus Therapeutics, Arvinas, BridgeBio Pharma and Coherus BioSciences, among others. Companies named in the 2024 Compensation Peer Group include Allogene Therapeutics, Arcus Biosciences, Cogent Biosciences, Mirati Therapeutics and Replimune Group, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Steven Hoerter President and Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Matthew Sherman Executive Vice President, Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Thomas Kelly Executive Vice President, Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Daniel Flynn Founder and Former Executive Vice President, Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Daniel Martin Senior Vice President, Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Steven Hoerter President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Dashyant Dhanak Executive Vice President, Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Matthew Sherman Executive Vice President, Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Thomas Kelly Executive Vice President, Chief Financial Officer and Treasurer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Daniel Flynn Founder and Former Executive Vice President, Chief Scientific Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Daniel Martin Senior Vice President, Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Daniel C. Martin | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Daniel C. Martin | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Daniel L. Flynn | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Daniel L. Flynn | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Dashyant Dhanak | — | ◇ | — | — | ◇ | — | — | ◇ |
| Dashyant Dhanak | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Matthew L. Sherman | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Matthew L. Sherman | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Steven L. Hoerter | — | ◇ | — | — | ◇ | — | — | ◇ |
| Steven L. Hoerter | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Thomas P. Kelly | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Thomas P. Kelly | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Daniel Martin | Option | ◇ | — | ◇ | 2/15/2031 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/17/2032 | |
| Option | ◇ | — | ◇ | 2/14/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/17/2030 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Matthew Sherman | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/17/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/14/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/15/2031 | |
| Option | ◇ | — | ◇ | 2/17/2030 | |
| Dashyant Dhanak | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 9/14/2033 | |
| Steven Hoerter | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 2/15/2031 | |
| Option | ◇ | — | ◇ | 2/14/2033 | |
| Option | ◇ | — | ◇ | 1/17/2032 | |
| Option | ◇ | — | ◇ | 2/17/2030 | |
| Daniel Flynn | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 2/14/2033 | |
| Option | ◇ | — | ◇ | 1/17/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/15/2031 | |
| Option | ◇ | — | ◇ | 2/17/2030 | |
| Thomas Kelly | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 2/15/2031 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/17/2032 | |
| Option | ◇ | — | ◇ | 2/14/2033 | |
| Option | ◇ | — | ◇ | 2/17/2030 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2023
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
James A. Bristol, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Ron Squarer Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Patricia L. Allen | ◇ | — | ◇ | — | — | — | ◇ |
Edward J. Benz Jr., M.D | ◇ | — | ◇ | — | — | — | ◇ |
Susan L. Kelley, M.D | ◇ | — | ◇ | — | — | — | ◇ |
John R. Martin | ◇ | — | ◇ | — | — | — | ◇ |
Dennis L. Walsh | ◇ | — | ◇ | — | — | — | ◇ |
Frank S. Friedman | ◇ | — | ◇ | — | — | — | ◇ |
Steven L. Hoerter served on the board in fiscal 2023 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
- Agios Pharmaceuticals AGIO
- Amicus Therapeutics FOLD
- Arvinas ARVN
- BridgeBio Pharma BBIO
- Coherus BioSciences CHRS
- EQRx EQRX
- Karyopharm Therapeutics KPTI
- Mersana Therapeutics MRSN
- NGM Biopharmaceuticals NGM
- Scholar Rock Holding Corporation SRRK
- Seres Therapeutics MCRB
- SpringWorks Therapeutics SWTX
- Y-mAbs Therapeutics YMAB
2024 Compensation Peer Group
- Allogene Therapeutics ALLO
- Arcus Biosciences RCUS
- Cogent Biosciences COGT
- Mirati Therapeutics MRTX
- Replimune Group REPL
- Syndax Pharmaceuticals SNDX
What this page does not include
Everything above is a fact Deciphera Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Deciphera Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
229 figures on this page, cited to the filing that reported them.
229 cited to the filing
Documents cited
- 0001654151-24-000012Director Compensation Table – 2023 · Employee Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year End · and 2 more sections
- 0001654151-23-000007Summary Compensation Table – 2022, 2021, and 2020 Fiscal Years
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Deciphera Pharmaceuticals executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/DCPH (accessed 2026).
Short form: data: Velarion
The paid brief for Deciphera Pharmaceuticals
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Deciphera Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Deciphera Pharmaceuticals discloses
The companies named in DCPH's own disclosed peer group.
Agios PharmaceuticalsAmicus TherapeuticsArvinasBridgeBio PharmaCoherus BioSciencesKaryopharm TherapeuticsMersana TherapeuticsNGM BiopharmaceuticalsScholar Rock Holding CorporationSeres TherapeuticsSpringWorks TherapeuticsY-mAbs TherapeuticsAllogene TherapeuticsArcus BiosciencesCogent BiosciencesReplimune GroupSyndax Pharmaceuticals
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}